Abstract:Objective To evaluate the efficacy and safety of daptomycin in the treatment of hematopathy associated with skin and soft tissue infection(SSTI). Methods Clinical data, laboratory test results as well as efficacy and safety of daptomycin in the treatment of hematopathy associated with SSTI in patients in a hospital from March 2018 to March 2019 were analyzed retrospectively, according to whether there was agranulocytosis or not, patients were divided into agranulocytosis group and non-agranulocytosis group, difference in cure rate between two groups was compared. Results A total of 18 patients with hematopathy complicated with SSTI were treated with daptomycin, 14 of whom (77.8%) were clinically cured; there was no significant difference in the cure rate between agranulocytosis group and non-agranulocytosis group (75.0% vs 80.0%, P>0.05). The median time of patients' temperature dropped by 1℃ was 12 (4-24) hours, and the median time of abatement of fever was 1.65 (0.2-4) days, adverse reaction related to daptomycin was not found. Conclusion Daptomycin is safe and effective in the treatment of hematopathy with SSTI, with few adverse reaction.